Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-23
2011-12-13
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S056000, C514S057000, C514S078000
Reexamination Certificate
active
08076312
ABSTRACT:
This invention provides a method of preventing asthma, allergic rhinitis, or chronic obstructive pulmonary disease in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a method of treating allergic rhinitis or chronic obstructive pulmonary disease in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
REFERENCES:
patent: 4604376 (1986-08-01), Teng
patent: 4624919 (1986-11-01), Kokusho
patent: 4654327 (1987-03-01), Teng
patent: 5064817 (1991-11-01), Yedgar et al.
patent: 5169636 (1992-12-01), Nanba et al.
patent: 5354853 (1994-10-01), Staveski
patent: 5401511 (1995-03-01), Margalit
patent: 5401777 (1995-03-01), Ammon et al.
patent: 5464942 (1995-11-01), Sakurai et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5512671 (1996-04-01), Piantadose
patent: 5587363 (1996-12-01), Henderson
patent: 5733892 (1998-03-01), Sakurai
patent: 5785975 (1998-07-01), Parikh
patent: 6022866 (2000-02-01), Falk et al.
patent: 6043231 (2000-03-01), Pruzanski et al.
patent: 6071532 (2000-06-01), Chaikof et al.
patent: 6162787 (2000-12-01), Sorgente et al.
patent: 6171614 (2001-01-01), Chaikof et al.
patent: 6180596 (2001-01-01), Tsao
patent: 6325385 (2001-12-01), Iwashita et al.
patent: 7101859 (2004-05-01), Yedgar et al.
patent: 6749813 (2004-06-01), David et al.
patent: 7141552 (2006-11-01), Yedgar et al.
patent: 0236951 (1987-09-01), None
patent: 0529659 (1993-03-01), None
patent: 0581281 (1994-02-01), None
patent: 0581282 (1994-02-01), None
patent: 1046394 (2000-10-01), None
patent: 04082893 (1992-03-01), None
patent: 09030970 (1997-02-01), None
patent: 09030979 (1997-02-01), None
patent: 2002345455 (2002-12-01), None
patent: 2003160498 (2003-03-01), None
patent: 2003335801 (2003-11-01), None
patent: 2004018841 (2004-01-01), None
patent: 2004170194 (2004-06-01), None
patent: WO 87/02777 (1987-05-01), None
patent: WO 87 02777 (1987-05-01), None
patent: WO 91/00289 (1991-01-01), None
patent: WO 96/04001 (1996-02-01), None
patent: WO 96/11670 (1996-04-01), None
patent: WO 9628544 (1996-09-01), None
patent: WO9628544 (1996-09-01), None
patent: WO9701330 (1997-01-01), None
patent: WO 9701330 (1997-01-01), None
patent: WO 97/48337 (1997-12-01), None
patent: WO9816198 (1998-04-01), None
patent: WO 9816198 (1998-04-01), None
patent: WO 98/51285 (1998-11-01), None
patent: WO 01/51003 (2001-07-01), None
patent: WO 01/91805 (2001-12-01), None
patent: WO 2005/084307 (2005-09-01), None
Albini, A, Iwamoto, Y, Kleinman, HK, Martin, GR, Aaronson, SA, Kozlowski, JM and McEwan, RN (1987) “A rapid in vitro assay for quantitating the invasive potential of tumor cells”Cancer Res47(12):3239-45.
Balsinde, J, Balboa, MA, Yedgar, S and Dennis, EA (2000) “Group V phospholipase A(2)-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D(1) macrophages”J Biol Chem275(7):4783-6.
Beck, G, Yard, BA, Schulte, J, Oberacker, R, Van Ackern, K, Van Der Woude, FJ, Krimsky, M, Kaszkin, M and Yedgar, S (2002) “Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane”Br J Pharmacol135(7):1665-74.
Brenner, T, Arnon, R, Sela, M, Abramsky, O, Meiner, Z, Riven-Kreitman, R, Tarcik, N and Teitelbaum, D (2001) “Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone”J Neuroimmunol115(1-2):152-60.
Brenner, T, Lisak, RP, Rostami, A, Pleasure, DE and Silberberg, DH (1986) “Astrocytes, oligodendrocytes, and Schwann cells share a common antigenic determinant that cross-reacts with myelin basic protein: identification with monoclonal antibody”J Neurosci6(7):1925-33.
Brenner, T, Poradosu, E, Soffer, D, Sicsic, C, Gazit, A and Levitzki, A (1998) “Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556”Exp Neurol154(2):489-98.
Cabanas, C and Hogg, N (1993) “Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte function-associated molecule 1”Proc Natl Acad Sci U S A90(12):5838-42.
Chen, WM, Soria, J, Soria, C, Krimsky, M and Yedgar, S (2002) “Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2)”FEBS Lett522(1-3):113-8.
Dan, P, Dagan, A, Krimsky, M, Pruzanski, W, Vadas, P. and Yedgar, S (1998) “Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers”Biochemistry37(17):6199-204.
Darville, T, Yedgar, S, Krimsky, M, Andrews, CW, Jr., Jungas, T and Ojcius, DM (2004) “Protection againstChlamydia trachomatisinfection in vitro and modulation of inflammatory response in vivo by membrane-bound glycosaminoglycans”Microbes Infect6(4):369-76.
Davidson, FF, Dennis, EA, Powell, M and Glenney, JR, Jr. (1987) “Inhibition of phospholipase A2 by “lipocortins” and calpactins. An effect of binding to substrate phospholipids”J Biol Chem262(4):1698-705.
Greaves MW and Camp RD (1988) “Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin.”Arch Dermatol Res280:S33-41.
Krimsky, M, Dagan, A, Aptekar, L, Ligumsky, M and Yedgar, S (2000) “Assessment of intestinal permeability in rats by permeation of inulin-fluorescein”J Basic Clin Physiol Pharmacol11(2):143-53.
Krimsky, M, Yedgar, S, Aptekar, L, Schwob, O, Goshen, G, Gruzman, A, Sasson, S and Ligumsky, M (2003) “Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor”Am J Physiol Gastrointest Liver Physiol285(3):G586-92.
Margolis-Nunno, H, Ben-Hur, E, Gottlieb, P, Robinson, R, Oetjen, J and Horowitz, B (1996) “Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates”Transfusion36(8):743-50.
Murthy, SN, Cooper, HS, Shim, H, Shah, RS, Ibrahim, SA and Sedergran, DJ (1993) “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin”Dig Dis Sci38(9):1722-34.
Okayasu, I, Hatakeyama, S, Yamada, M, Ohkusa, T, Inagaki, Y and Nakaya, R (1990) “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice”Gastroenterology98(3):694-702.
Schmiel, DH and Miller, VL (1999) “Bacterial phospholipases and pathogenesis”Microbes Infect1(13):1103-12.
Schnitzer, E, Dagan, A, Krimsky, M, Lichtenberg, D, Pinchuk, I, Shinar, H and Yedgar, S (2000) “Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lipids to oxidation”Chem Phys Lipids104(2):149-60.
Schnitzer, E, Yedgar, S, Danino, D, Talmon, Y and Lichtenberg, D (1999) “The Interaction of hyaluronic-phosphatidylethanolamine with low density lipoprotein (LDL) and its effect on copper induced LDL oxidation”Biophysical Journal76(1): Part 2.
Schnitzer, E, Pinchuk, I, Fainaru, M, Lichtenberg, D and Yedgar, S (1998) “LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro”Free Radic Biol Med24(7-8):1294-303.
Yard, BA, Yedgar, S, Scheele, M, Van Der Woude, D, Beck, G, Heidrich, B, Krimsky, M, Van Der Woude, FJ and Post, S (2002) “Modulation of IFN-gamma-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid”Transplantation73(6):984-92.
Yedgar, S, Lichtenberg, D and Schnitzer, E (2000) “Inhibition of phospholipase A(2) as a therapeutic target”Biochim Biophys Acta
Pearl Cohen Zedek Latzer LLP
Saeed Kamal
Yissum Research Development Company of the Hebrew University of
LandOfFree
Use of lipid conjugates in the treatment of disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of lipid conjugates in the treatment of disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lipid conjugates in the treatment of disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254601